Lenalidomide in non-Hodgkin lymphoma: biologic perspectives and therapeutic opportunities
Cet article passe en revue les essais cliniques en cours évaluant le lénalidomide, seul ou en combinaison, pour le traitement de patients atteints d'un lymphome non hodgkinien
Lenalidomide is an immunomodulatory analog (IMiDsTM) with activity in lymphoid malignancies occurring primarily through immune modulation (e.g., T-cell immune synapse enhancement and NK-cell/T-cell effector augmentation) and anti-proliferative effects. FDA approved for bortezomib-resistant, relapsed/refractory mantle-cell lymphoma, lenalidomide has demonstrated efficacy in several additional lymphoma subtypes. There are a multitude of ongoing clinical trials examining lenalidomide alone or in combinatorial therapy. It will be important in these studies to delineate reliable, predictive biomarkers to most optimally integrate lenalidomide into lymphoma treatment paradigms.